Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

Second Affiliated Hospital of Wenzhou Medical University

Status: Not yet enrolling

Conditions: Crohn Disease

Study type: Observational

Funder types: Other

Identifiers

NCT06739278

SAHoWMU-CR2024-01-222

Details and patient eligibility

About

This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.

Full description

Participants in the study receive ustekinumab injections as part of routine medical care. The study just observes the efficacy retrospectively and does not interfere with treatment.

Enrollment: 119 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of Perianal Fistulizing Crohn's Disease
• Receive ustekinumab therapy

Exclusion criteria

• Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
• Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.
• Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.
• Combined with malignant tumor
• Clinical data missing ≥30% or no follow-up